Development of a dissolution method for lumefantrine and artemether in immediate release fixed dose artemether/lumefantrine tablets by Yohannes, Sileshi Belew et al.
Belew et al. Malar J          (2020) 19:139  
https://doi.org/10.1186/s12936-020-03209-5
RESEARCH
Development of a dissolution method 
for lumefantrine and artemether in immediate 
release fixed dose artemether/lumefantrine 
tablets
Sileshi Belew1,2, Sultan Suleman1*, Markos Duguma1, Henok Teshome1, Evelien Wynendaele2, Luc Duchateau3 
and Bart De Spiegeleer2*
Abstract 
Background: Dissolution of artemether (ART) and lumefantrine (LUM) active pharmaceutical ingredients (APIs) in 
fixed dose combination (FDC) ART/LUM tablets is one of the critical quality attributes. Thus, the verification of the 
release profile of ART and LUM from FDC ART/LUM tablets using a robust and discriminatory dissolution method is 
crucial. Therefore, the aim of this study was to develop and validate an appropriate dissolution method for quality 
control of FDC ART/LUM tablets.
Methods: The dissolution medium was selected based on saturation solubility data and sink conditions. The effect of 
agitation speed, pH and surfactant concentration on the release of ART and LUM was evaluated by employing a two-
level factorial experiment. The resulting final method was validated for linearity, precision, robustness and API stability. In 
addition, the discriminatory power of the method was evaluated using expired and unexpired FDC ART/LUM products.
Results: A suitable dissolution profile of FDC ART/LUM tablets was obtained in 900 ml HCl (0.025 N, pH 1.6) with 
1%Myrj 52 using paddle method at 100 rpm and 37 °C. ART and LUM were analysed using a HPLC method with UV 
detection at wavelengths of 210 and 335 nm, respectively. The results from the stability study showed that ART and 
LUM were sufficiently stable in HCl (0.025 N, pH 1.6) with 1%Myrj 52 at 37 °C. The method was linear  (r2 = 0.999) over 
the concentration range of 6.25–100 μg/ml. The results for precision were within the acceptance limit (%RSD < 2). 
The percent relative standard deviation (< 2%) and statistically non-significant (p > 0.05) difference in release of 
ART and LUM observed between deliberately changed dissolution method settings (pH = 1.6 ± 0.2 or agitation 
speed = 100 ± 2) and optimized dissolution conditions revealed the robustness of the dissolution method. The 
method was capable to discriminate among different FDC ART/LUM products with different quality.
Conclusions: The developed dissolution method is robust and discriminatory. It can be used in the quality evalua-
tion of FDC ART/LUM tablets.
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Background
Artemether (ART) and lumefantrine (LUM) are anti-
malarial agents that demonstrate synergistic anti-malar-
ial activity resulting in rapid clearance of parasitaemia 
and prevention of recrudescence [1–5]. Thus, fixed dose 
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combination (FDC) ART/LUM (20 mg/120 mg) products 
are widely used as the first-line treatment for uncompli-
cated Plasmodium falciparum malaria [6–9]. ART (logP 
3.53) and LUM (logP 9.19, pKa 8.73 and 13.49) [10] are 
classified as Biopharmaceutical Classification System 
(BCS) class IV drugs [11]. Hence, permeability and solu-
bility/dissolution are critical attributes [12, 13] that can 
influence the rate and extent of drug absorption and bio-
availability [14–16].
FDC ART/LUM products are available as solid oral 
dosage forms like tablets. The dissolution of drugs can be 
influenced by various API and formulation factors, such as 
particle size variability of the APIs or granulation technol-
ogy [17–21], as well as by dissolution-method variables, 
such as pH, buffer capacity, ionic strength and presence 
of surfactants [22]. Hence, it is important to establish the 
in  vitro dissolution conditions that help to discriminate 
significant ingredients and manufacturing process vari-
ability in an attempt to assure quality consistency, and 
possibly guarantee also to some extent the in vivo perfor-
mance, of FDC ART/LUM solid oral dosage forms.
Dissolution methods for FDC ART/LUM tablets are 
currently missing in official monographs and available 
methods described in the literature need relative long 
dissolution times (120 min), use independent dissolution 
conditions for each API or inadequately consider the rel-
ative effect of dissolution method variables [23, 24]. Con-
sequently, developing an appropriate dissolution method 
for FDC ART/LUM products is crucial. The present 
study was therefore aimed to develop and validate a QC-
relevant, efficient, robust and discriminatory dissolution 
method for ART and LUM in FDC ART/LUM tablets.
Methods
Drugs/chemicals/reagents/solvents
ART and LUM working reference standards were 
obtained from Dafra Pharma International (B-2300 
Turnhout, Belgium) through Drug Quality and Reg-
istration (DruQuaR) laboratory, University of Ghent, 
Belgium. Ultrapure water (18.2  MΩ. cm at 25  °C) was 
prepared in Jimma University Laboratory of Drug Qual-
ity (JuLaDQ) using Nanopure Analytical ultrapure water 
system (model number: D11901 (7143), Thermo fisher 
Scientific). Acetonitrile (HPLC grade, Fisher Scientific), 
Tween 80 (AcrosOrganics), Benzalkonium chloride 
(Fagron), Sodium lauryl sulfate (Sigma-aldrich), Poly-
oxyl 40 Stearate (Myrj 52) (Sigma-aldrich), Hydrochlo-
ric acid (Sigma-aldrich), Orthophosphoric acid (Fluka) 
and Tetrahydrofuran (HPLC grade, Sigma-aldrich) were 
used as received. FDC ART/LUM (20  mg ART/120  mg 
LUM) products were used. Detailed information on the 
five FDC ART/LUM products investigated in this study is 
presented in Additional file 1: Table S1.
Experimental
Mass uniformity
The mass uniformity of tablet samples of each brand of 
FDC ART/LUM products was conducted according 
to the method given in the European Pharmacopoeia 
[25]. Randomly selected tablets (n = 20) were individu-
ally weighed with a calibrated balance (Mettler Toledo, 
AL204-1C, Switzerland). The results were evaluated 
against the European Pharmacopoeia specifications (i.e. 
the deviation of individual masses from average mass 
should not exceed ± 7.5%, with only maximum 2 tablets 
allowed to deviate maximally ± 15%).
Amount of active compound
The amount of ART and LUM in samples of FDC ART/
LUM tablets was determined based on the previously 
published HPLC method [26]. In brief, the analysis of 
ART and LUM was conducted using Agilent 1260 Infin-
ity Series HPLC system (Agilent Technologies, Santa 
Clara, California, USA) equipped with a Halo-RP-Amide 
column (50 × 4.6 mm, 2.7 µm) coupled to a diode-array 
detector (DAD). The detection wavelengths of ART and 
LUM were 210 and 335 nm, respectively. The flow rate, 
injection volume, run time and column temperature were 
1 ml/min, 3 µl, 5 min and 30 °C, respectively. The mobile 
phase used was a mixture of acetonitrile/0.001 M potas-
sium phosphate buffer pH 3.0 (52:48% v/v).
System suitability tests (SST)
System suitability for analysis of ART and LUM was eval-
uated according to the European Pharmacopoeia method 
[27]. The symmetry factor  (As) of principal peaks was cal-
culated using the following formula:
where  Wx = peak width at 5% of reference standard peak 
height measured from the base line, d = base line dis-
tance between the perpendicular dropped from the peak 
maximum and the leading edge of the peak at 5% of peak 
height measured in the same unit as  Wx. The specifica-
tion was an  As value of maximally 1.5. In addition, per-
cent relative standard deviation (%RSD) of replicate 
injections (n = 6) of reference standards were calculated 
and compared against the European Pharmacopoeia 
specification limit (i.e. %RSD of six injections should 
be ≤ 1.2).
Preparation of ART and LUM standard solutions
Working reference standard of ART (20 mg) and LUM 
(120 mg) were individually added into a 100.0 ml volu-
metric flask, dissolved in 80 ml tetrahydrofuran (HPLC 
As =Wx/2d
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grade, Sigma-aldrich), sonicated for 15  min, filled to 
volume with mobile phase (acetonitrile/0.001 M potas-
sium phosphate buffer pH 3.0 (52:48% v/v)), filtered 
using 0.45 µm Whatman filter paper (CAT No 1102090) 
and analysed using HPLC.
Preparation of sample solutions
Tablet samples (n = 20) were weighed and grounded 
into fine powder with clean and dry mortar and pestle 
[28]. An accurately weighed portion of powder equiva-
lent to 20 mg ART and 120 mg LUM was individually 
added into 100.0 ml volumetric flask, dissolved in 80 ml 
of tetrahydrofuran (HPLC grade, Sigma-aldrich), soni-
cated for 15  min, filled to volume with mobile phase 
(acetonitrile/0.001  M potassium phosphate buffer pH 
3.0 (52:48% v/v)), filtered using 0.45 µm Whatman filter 
paper (CAT No 1102090) and analysed using HPLC.
Equilibrium solubility
An equilibrium solubility study was conducted by the 
shake-flask method [29]. LUM (10 mg) was added into 
50 ml conical flask and dissolved in 10 ml 1% w/v sur-
factant/HCl (pH 1.2) and 1–2% w/v surfactant/HCl (pH 
2.3), while ART (10 mg) was added into 50 ml conical 
flask and dissolved in 0.5–2% surfactant/HCl (pH 1.2 
or 2.3) and 0.5–1% w/v surfactant/buffer (pH 4.5 or 
6.8). The flasks were incubated at 37 °C for 24 h whilst 
shaking at 100  rpm. The samples were rapidly filtered 
using 0.45  µm PVDF (polyvinylidene fluoride) syringe 
filter, suitably diluted (2.5 ± 0.5 times) with acetonitrile 
and analysed at the auto-sampler temperature of 37 °C 
using HPLC system (Waters Alliance 2695 Separations 
Module Milford, MA, USA) equipped with a Halo-RP-
Amide column (50 × 4.6  mm, 2.7  µm) as described in 
previous HPLC method [26].
Solution stability
The solution stability was evaluated by analysing the 
concentration of ART and LUM (mixture) in dissolution 
medium stored at 37 °C for at least 24 h.
Dissolution of ART and LUM from FDC ART/LUM tablets
Screening study
Screening experiments were conducted using dissolution 
medium (Myrj 52/HCl) selected based on the results of 
equilibrium solubility of ART and LUM. Agitation speed 
(A1), pH (A2) and surfactant concentration (A3) were the 
factors used for the release of ART and LUM. Three-way 
factorial (each factor with two levels) experiment (Design 
Expert 6.0.1 software (Stat Ease. Inc.)) was employed to 
determine the best combination of factors for the release 
of ART and LUM. The factor settings for Design of Exper-
iment (DoE) are presented in Additional file 2: Table S2. 
The dissolution was conducted using USP type II (Paddle) 
method (RC-8 dissolution apparatus, China). The volume 
of dissolution medium and bath temperature were 900 ml 
and 37 °C, respectively. FDC ART/LUM tablets (Ipca Lab-
oratories, India, batch no. DYI 478058, within shelf-life 
period) (n = 2) were subjected to the different dissolution 
conditions. Samples (10 ml) were withdrawn at 30, 60, 90 
and 120  min, filtered through 0.45  µm Whatman filter 
paper (CAT No 1102090), diluted with acetonitrile and 
analysed using the HPLC method [26]. Agilent 1260 Infin-
ity series HPLC system coupled with a Halo-RP-Amide 
column (50 × 4.6  mm, 2.7  µm) and diode-array detector 
(DAD) was used. The mobile phase used was acetonitrile 
(HPLC grade, Sigma-Aldrich)/(0.001 M potassium phos-
phate buffer pH 3.0) (58:42% v/v). The detection wave-
lengths used for the analysis of ART and LUM were 210 
and 335 nm, respectively. The sample temperature in the 
auto-injector was 37  °C. The column temperature, flow 
rate, injection volume, run time were 30  °C, 1.5 ml/min, 
20 µl and 12 min, respectively.
Optimization of dissolution conditions
Since the target dissolution of both ART and LUM from 
FDC ART/LUM tablets was set at Q ≥ 80% at 60  min, 
optimal dissolution conditions giving the desired 
response were selected and optimized using a desirability 
approach [Design Expert 6.0.1 software (Stat Ease. Inc.)].
Discriminatory power
The discriminatory power of the optimized dissolution 
conditions was evaluated using commercially avail-
able FDC ART/LUM products (4 unexpired, before the 
labelled expiry date, and 1 expired, beyond the labelled 
expiry date). Area under the dissolution curve (AUC), 
dissolution efficiency (DE) and mean dissolution time 
(MDT) of different FDC ART/LUM products were esti-
mated using KinetDS software program (KinetDS 3.0). 
The results were compared using ANOVA based data 
evaluation. In addition, release (%) of ART and LUM 
at 60 min from different FDC ART/LUM products was 
compared using post hoc multiple comparison test.
Validation of the dissolution procedures
The applied HPLC method was based on a previously 
developed and validated method for the assay of both 
API in tablets [26]. As in this study, dissolution samples 
were to be analysed, as well as the operational condi-
tions were slightly adapted to meet the SST, the adapted 
method was revalidated.
Linearity and range The HPLC method [26] used for 
the quantification of ART and LUM in the dissolution 
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samples was evaluated for linearity by analyzing the 
concentrations of ART and LUM ranging from 6.25 to 
100  μg/ml. The regression line was assessed by deter-
mining the 95% confidence interval (95% CI) of slope 
and intercept parameters as well as by evaluating F-lack 
of fit and the residual plot.
Precision/repeatability Precision was determined 
by repeatability and intermediate precision stud-
ies. Repeatability of the method was done by multiple 
measurements (n = 6) of the sample of tablets by the 
same analyst, while intermediate precision was done 
by performing the dissolution test on the same sample 
of tablets on different days by at least two analysts. The 
results were compared against the acceptance limits 
given in the European Pharmacopoeia for assaying APIs 
(%RSD ≤ 1.2) [27].
Robustness Robustness was studied by evaluating the 
effect of small but deliberate variations (i.e. the pH of 
the dissolution medium (± 0.2) and paddle rotation 
speed (± 2  rpm)) in the optimized dissolution condi-
tions. Percent relative standard deviation (%RSD) was 
calculated and compared against the suggested  %RSD 
(< 2) [30]. Comparative statistical analysis of the results 
obtained from two dissolution conditions (i.e. optimized 
vs. optimized with deliberate change in parameters) was 
performed using Student’s t test (p < 0.05).
Statistical analysis
Statistical analysis was performed using Statistix-8 
software and SPSS version 20.
Results
Mass uniformity
The results of mass uniformity (mean: 244.00 to 291.95 
and SD: 1.52 to 9.67, n = 20) of five commercially avail-
able FDC ART/LUM products revealed that all products 
comply with the European Pharmacopoeia specification 
limits (i.e. the deviation of individual masses from aver-
age mass should not exceed ± 7.5%, with only maximum 
2 tablets allowed to deviate maximally ± 15%). The results 
of mass uniformity of five commercially available FDC 
ART/LUM products are presented in Additional file  3: 
Table S3.
Amount of active compounds
The results of amount of ART and LUM in FDC ART/
LUM tablets is presented in Table  1. The assay results 
revealed that all samples comply with the generally 
accepted specification criteria for both ART and LUM, 
i.e. percentage label claim (%l.c.) between 90 and 110%.
Equilibrium solubility
The results of the equilibrium solubility of ART and 
LUM are presented in Table  2. The results revealed 
Table 1 Results of  amount of  active compounds in  FDC 
ART/LUM tablets
a Expired product, l.c.: label claim
Product ART LUM
% l.c. (%RSD) % l.c. (%RSD)
Comether® 104.6 (0.73) 109.3 (0.72)
Artel-L® 108.1 (1.06) 103.2 (2.15)
Artemine® 104.7 (2.92) 106.1 (0.04)
ART/LUM 110.1 (0.34) 109.8 (0.25)
ART/LUM-Ea 90.1 (0.66) 95.8 (0.63)
Table 2 Results of ART and LUM APIs solubility in different 
media as determined by HPLC
# Medium Solubility 
(µg/ml)
ART 
1 0.5% w/v Myrj 52/HCl (pH 1.2) 151
2 1% w/v Myrj 52/HCl (pH 1.2) 181
3 1% w/v Myrj 52/HCl (pH 2.3) 290
4 1.5% w/v Myrj 52/HCl (pH 2.3) 452
5 2% w/v Myrj 52/HCl (pH 2.3) 652
6 0.5% w/v SLS/HCl (pH 1.2) 323
7 1% w/v SLS/HCl (pH 1.2) 337
8 0.5% w/v Myrj 52/0.05 M ammonium acetate buffer (pH 
4.5)
8
9 1% w/v Myrj 52/0.05 M ammonium acetate buffer (pH 
4.5)
33
10 0.5% w/v SLS/0.05 M ammonium acetate buffer (pH 4.5) 138
11 1% w/v SLS/0.05 M ammonium acetate buffer (pH 4.5) 219
12 0.5% w/v Myrj 52/0.05 M sodium phosphate buffer (pH 
6.8)
22
13 1% w/v Myrj 52/0.05 M sodium phosphate buffer (pH 6.8) 37
14 0.5% w/v SLS/0.05 sodium phosphate buffer (pH 6.8) 5
15 1% w/v SLS/0.05 M sodium phosphate buffer (pH 6.8) 5
16 0.5% w/v Tween80/0 0.05 M ammonium acetate buffer 
(pH 4.5)
24
17 1% w/v Tween 80/0.05 M ammonium acetate buffer (pH 
4.5)
23
18 0.5% w/v Tween 80/HCl (pH 1.2) 10
19 1% w/v Tween 80/HCl (pH 1.2) 17
LUM
20 1% w/v Myrj 52/HCl (pH 2.3) 626
21 1.5% w/v Myrj 52/HCl (pH 2.3) 813
22 2% w/v Myrj 52/HCl (pH 2.3) 1033
23 1% w/v Tween 80/HCl (pH 1.2) 112
24 1% w/v Benzalkonium chloride/HCl (pH 1.2) 93
25 1% w/v Sodium lauryl sulfate/HCl (pH 1.2) 59
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that relatively higher solubility of ART and LUM was 
observed in 1–2% Myrj 52/acidic pH. This reflects that 
the presence of surfactant in acidic pH enhances solubil-
ity of both APIs. Both APIs were stable in the dissolution 
medium for 24  h. The percentage differences obtained 
(ART: 1.5–1.8%, LUM: 0.9–1.4%) at the end of 24 h from 
the initial (0 h) value suggest stability of both compounds 
in the dissolution medium.
Dissolution of ART and LUM from FDC ART/LUM tablets
Screening study
The individual response results of the DoE experiment 
are presented in Additional file 4: Table S4. Typical dis-
solution profiles of ART and LUM from unexpired FDC 
ART/LUM tablets under the different DoE-experimental 
conditions are presented in Figs.  1 and 2, respectively. 
At 60  min, maintaining the agitation speed at 100  rpm 
Fig. 1 Dissolution profile (mean, n = 2) of ART API in FDC ART/LUM tablets (Ipca Laboratories, India, batch no. DYI 478058) in 900 ml dissolution 
media at 37 ± 0.5 °C) using USP apparatus II (paddle). (Legend from left to right: rpm pH Myrj52 concentration)
Fig. 2 Dissolution profile (mean, n = 2) of LUM API in FDC ART/LUM tablets (Ipca Laboratories, India, batch no. DYI 478058) in 900 ml dissolution 
media at 37 ± 0.5 °C using USP apparatus II (paddle). (Legend from left to right: rpm pH Myrj52 concentration)
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and surfactant concentration at 1.5% in the DoE-experi-
mental conditions, decreasing the pH of the dissolution 
medium by 2 units (3.3 to 1.3) increased the dissolution 
of LUM from 13.0% to 87.2%, and slightly decreased the 
dissolution of ART from 87.6 to 80.9%.
The equations for response factor (% release at 60 min) 
of ART and LUM are given below.
Where Y1 and Y2 are % release of ART and LUM, 
respectively. A1, A2 and A3 are coded variables with two 
levels representing agitation speed (50 to100 rpm, cor-
responding to coded A1 values − 1 to + 1), pH (1.3 to 
3.3 corresponding to coded A2 values − 1 to + 1,) and 
surfactant concentration (0.5 to 1.5%, corresponding to 
coded A3 values − 1 to + 1), respectively.
The model used to fit the response variable (i.e. 
release of ART and LUM at 60  min) was significant 
(p < 0.0001) to represent the relationship between the 
response and the independent variables. The model 
F-value (ART: 119, LUM: 2107) suggested significance 
of the model. The  R2 value (ART: 0.996, LUM: 0.999) 
indicated that only 0.4 (ART) and 0.1% (LUM), of the 
total variation of response data was not explained by 
the model. Agitation speed (A1), (Eq.  1), respectively 
pH (A2) (Eq. 2), demonstrated a relatively higher effect 
(1)
Y 1 = 68.6+ 15.8A1+ 4.2A2+ 3.7A3
+ 3.8A1A2+ 1.5A1A3− 3.8A2A3
(2)
Y 2 = 42.8+ 8.2A1− 31.4A2− 3.3A3− 7.1A1A2
+ 9.3A1A3+ 5.2A2A3− 3.4A1A2A3
Table 3 Effect of  independent factors on  the  release 
of ART from FDC ART/LUM tablets
Time (min) Factor settings Mean (%) 
release
A1 A2 A3
30 100 3.3 1.5 87.65a
100 1.3 1.5 80.88ab
100 3.3 0.5 77.70b
100 1.3 0.5 64.58c
50 1.3 1.5 46.92d
50 3.3 1.5 45.87d
50 1.3 0.5 44.72de
50 3.3 0.5 35.86e
LSD (0.05) 9.3
CV 3.88
p-value 0.01
A2 A3 Mean (%) 
release
60 3.3 1.5 73.00a
3.3 0.5 72.63a
1.3 1.5 71.71a
1.3 0.5 57.15b
LSD (0.05) 6.36
CV 4.1
p-value 0.001
A1 A2 Mean (%) release
100 3.3 92.52a
100 1.3 76.41b
50 3.3 53.12c
50 1.3 52.45c
LSD (0.05) 6.36
CV 4.1
p-value 0.001
A2 A3 Mean (%) 
release
90 3.3 1.5 82.59a
1.3 1.5 77.83b
3.3 0.5 76.56b
1.3 0.5 60.73c
LSD (0.05) 4.14
CV 2.46
p-value 0.000
A1 A2 Mean (%) release
100 3.3 94.17a
100 1.3 79.15b
50 3.3 64.98c
50 1.3 59.42d
LSD (0.05) 6.36
CV 4.1
p-value 0.000
Table 3 (continued)
A2 A3 Mean (%) 
release
120 3.3 1.5 93.03a
3.3 0.5 83.40b
1.3 1.5 81.26b
1.3 0.5 65.69c
LSD (0.05) 4.47
CV 2.44
p-value 0.01
A1 A3 Mean (%) release
100 1.5 94.01a
100 0.5 87.05b
50 1.5 80.27c
50 0.5 62.03d
LSD (0.05) 4.47
CV 2.44
p-value 0.000
Means with the same letters are not significantly different from each other
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on the release of ART, respectively LUM, than the other 
variables.
The results of the effects of independent factors on the 
release of ART and LUM from FDC ART/LUM product 
(Ipca Laboratories, India, batch no. DYI 478058) are pre-
sented in Tables 3 and 4, respectively. 
Considering the results at 60  min, at lower pH (1.3), 
the change in surfactant concentration from 1.5 to 0.5% 
decreased release of ART (71.7 to 57.1%). In addition, at 
high agitation speed (100  rpm), the change in pH from 
3.3 to 1.3 decreased release of ART (92.5 to 76.4%). For 
LUM, at high agitation speed (100  rpm) and low pH 
(1.3), change in surfactant concentration from 1.5 to 0.5% 
decreased its release from 93.3 to 85.2%.
Contour plots showing the interaction effect of factors 
on release of ART and LUM at 60 min are presented in 
Figs. 3 and 4, respectively. Figure 3 shows that an increase 
in agitation speed from 60 to 100  rpm with increase in 
pH from 2.3 to 3.3 increased the release (%) of ART. Fig-
ure 4 shows that an increase in agitation speed from 70 to 
100 rpm and a decrease in pH from 1.8 to 1.3 increased 
the release (%) of LUM. 
Discriminatory power
The release profiles of ART and LUM from FDC ART/
LUM products, subjected to the same dissolution con-
ditions, are presented in Fig.  5. Post-hoc multiple com-
parisons test on release (%) (at 60 min) of ART and LUM 
from different FDC ART/LUM products are presented 
in Additional file  5: Table  S5. The results of 95% CI for 
the mean (%) release of ART and LUM at different time 
points are presented in Additional file  6: Table  S6. At 
60  min, the release of ART from different FDC ART/
LUM products ranges from 63.60% (95% CI 62.62–64.58) 
to 83.83% (95% CI 82.75–84.91), respectively, while the 
release of LUM ranges from 60.68% (95% CI 59.33–62.03) 
to 88.82% (95% CI 86.29–91.34%).
The results of pair-wise comparison of means of area 
under the dissolution curve (AUC), dissolution efficiency 
(DE) and mean dissolution time (MDT) of ART and LUM 
from different FDC ART/LUM products estimated using 
KinetDS software program (KinetDS 3.0) are presented 
in Additional file 7: Table S7.
Validation of the method
Linearity. The linearity calibration curve for the method 
indicated the fitness-for-use of the applied method. The 
95% CI for the regression slope (2.81, 95% CI 2.73 to 
2.88), y-intercept (− 4.99, 95% CI − 1.05 to − 8.93) and 
ANOVA F-value of 13680.79 of ART and the 95% CI 
for the regression slope (21.35, 95% CI 20.93 to 21.77), 
y-intercept (− 22.33, 95% CI 20.93 to 44.13) and ANOVA 
F-value of 25871.1 as well as  R2 value of 0.999 proved a 
Table 4 Effect of  independent factors on  the  release 
of LUM from FDC ART/LUM tablets
Means with the same letters are not significantly different from each other
Time (min) Factor settings Mean 
(%) drug 
releaseA1 A2 A3
30 100 1.3 1.5 87.24a
100 1.3 0.5 74.81b
50 1.3 0.5 70.29b
50 1.3 1.5 33.98c
100 3.3 1.5 13.05d
50 3.3 0.5 9.82de
50 3.3 1.5 4.14e
100 3.3 0.5 3.68e
LSD (0.05) 8.84
CV 6.02
p-value 0
60 100 1.3 1.5 93.27a
100 1.3 0.5 85.2b
50 1.3 0.5 81.08b
50 1.3 1.5 37.77c
100 3.3 1.5 20.36d
50 3.3 0.5 14.32e
50 3.3 1.5 6.39f
100 3.3 0.5 4.76f
LSD (0.05) 5.37
CV 3.17
p-value 0
90 100 1.3 1.5 96.68a
100 1.3 0.5 90.52b
50 1.3 0.5 86.11b
50 1.3 1.5 39.63c
100 3.3 1.5 26.23d
50 3.3 0.5 17.44e
50 3.3 1.5 8.25f
100 3.3 0.5 7.07f
LSD (0.05) 5.56
CV 3.03
p-value 0
120 100 1.3 1.5 99.83a
100 1.3 0.5 94.96ab
50 1.3 0.5 92.83b
50 1.3 1.5 40.58c
100 3.3 1.5 28.47d
50 3.3 0.5 20.61e
50 3.3 1.5 10.56f
100 3.3 0.5 7.39f
LSD (0.05) 5.14
CV 2.63
p-value 0
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strong positive linear relationship. In addition, random 
pattern of the residual plot showed a good fit of the linear 
model to the data.
Precision/repeatability The %RSD for repeatability of 
the HPLC method used for the quantification of ART 
and LUM in dissolution samples at 60 min was within the 
specification limit (%RSD ≤ 1.2). The results of %RSD for 
the repeatability and intermediate precision are presented 
in Table 5.
Robustness The %RSD values (< 2%) and the statistically 
non-significant (p > 0.05) difference between the release 
(%) profile of ART and LUM APIs in two dissolution con-
ditions (optimized vs. optimized with deliberate change 
in parameters) revealed the robustness of the dissolution 
conditions. The results of release profile of ART and LUM 
are presented in Table 6.
Discussion
Dissolution testing is an important analytical tool used 
to verify the release of API from solid oral dosage forms 
and evaluate the impact of formulation composition and 
process parameters on the in vitro release of API [31, 32]. 
In the present study, a dissolution method for the in vitro 
dissolution of ART and LUM simultaneously from FDC 
ART (20 mg)/LUM (120 mg) tablets is developed.
The results of saturation solubility indicate that the 
solubility of ART and LUM in acidic pH (2.3) with 1% 
Myrj 52 was 290 and 626 µg/ml, respectively. This reflects 
that this medium maintains the sink conditions of both 
APIs that could ensure the minimum solubility required 
for ART (60  µg/ml) and LUM (360  µg/ml) from FDC 
ART (20  mg)/LUM (120  mg) tablets in 900  ml volume 
dissolution medium. The results of solution stability 
indicate that both APIs are stable in the selected disso-
lution medium at 37  °C. Since the factorial design helps 
to study the independent and interactions effects of 
factors [33], three factors (i.e. agitation speed, pH and 
Fig. 3 Contourplots showing the influence of interaction of factorson release (%) of ART API at 60 min
Fig. 4 Contour plots showing the influence of interaction of factors on release (%) of LUM API at 60 min
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surfactant) were evaluated by employing two level fac-
torial design. From the equation of the model obtained 
using the experimental results of release of ART and 
LUM at 60  min, it is seen that, keeping all other terms 
constant, a unit increase (50 rpm: − 1 to + 1) in agitation 
speed could increase the release of ART by 15.8%. While 
a unit increase in pH could decrease the release of LUM 
by 31.4%. This suggests that agitation speed has a rela-
tively strong influence on the release of ART, while pH is 
the most important variable for LUM.
The results obtained from the ANOVA-based data 
evaluation applied to different FDC ART/LUM prod-
ucts revealed differences in release of ART and LUM 
at 60  min, AUC, DE and MDT among FDC ART/LUM 
products. This points to differences in pharmaceutical 
attributes (API, formulation and/or manufacturing pro-
cesses) among the different FDC ART/LUM products 
and suggests the discriminatory power of the developed 
dissolution method. Therefore, the developed dissolution 
method is considered appropriate for testing batch-to-
batch quality consistency [34, 35]. In addition, a discrimi-
natory dissolution method might in principle reflect the 
in  vivo performance of drugs. However, since factors 
governing in vitro and in vivo drug release are not simi-
lar [36–38], the in vitro release profile of a product is not 
necessarily related to its in  vivo behavior. Especially for 
BCS (biopharmaceutical classification system) class IV 
drugs, such as ART and LUM, there is often not a well-
established correlation. In addition, the typical media 
Fig. 5 Dissolution profile (n = 6) of ART and LUM APIs in FDC ART/LUM tablets in 900 ml (1% Myrj 52/HCl (pH 1.6) at 37 ± 0.5 °C, 100 rpm) using USP 
II apparatus. a ART/LUM (unexpired), b  Comether®, c  Artemine®, d Artel-L® and e ART/LUM-E (expired) products
Table 5 Dissolution results at  60  min of  ART and  LUM 
from FDC ART/LUM tablets
FDC ART/LUM tablets (Ipca Laboratories, India, batch no. DYI 478058) were used
# % Drug release (n = 6)
Analyst 1 Analyst 2 Analyst 1 Analyst 2
ART ART LUM LUM
1 85.27 80.24 84.63 81.22
2 82.63 84.41 82.02 82.85
3 82.42 82.44 85.73 88.82
4 83.60 85.42 83.53 87.01
5 82.42 82.44 81.46 82.17
6 86.78 83.12 86.34 85.23
Mean 83.85 83.01 83.95 84.55
SD 1.8 1.79 1.97 2.98
%RSD 2.15 2.16 2.35 3.52
Mean 83.43 84.25
SD 0.59 0.42
%RSD 0.35 0.50
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volume (900 ml) has little bio-relevance as fasted gastric 
and intestinal volume is about 500 ml, and differences in 
hydrodynamic mixing efficiency were observed using dif-
ferent volumes [39].
The %RSD values (< 2) and the statistically non-sig-
nificant (p > 0.05) difference between release of ART or 
LUM in two dissolution conditions (optimized vs. modi-
fied with deliberate changes in parameters), in the pre-
sent study reflect that the developed method is robust 
enough to allow normal variability in routine testing. This 
implies that at normal operation conditions, the devel-
oped method could not lead to unnecessary rejection 
of products. The proposed dissolution method allowing 
the simultaneous dissolution profiling of ART and LUM 
in FDC ART/LUM tablets is using the USP apparatus 
II (paddle) in HCl (0.025 N, pH 1.6) with 1% Myrj 52 as 
dissolution medium at 100 rpm and 37 °C. Based on the 
results of release of ART and LUM in commercially avail-
able FDC ART/LUM tablets subjected to the developed 
dissolution method, Q ≥ 80% at 60 min is suggested as a 
quality acceptance limit for the dissolution test of ART 
and LUM from FDC ART/LUM tablets, which is con-
sistent as the QC quality attribute of most immediate-
release products [40]. Since dissolution test of ART and 
LUM is currently missing in an official monographs, the 
developed dissolution method could be considered suit-
able for quality control and dissolution profile compari-
son of different commercial formulations of FDC ART/
LUM products.
Conclusion
The results of the present study revealed that the 
developed and validated dissolution method with 
HPLC–UV determination was capable to distinguish 
significant formulation variations and allow normal 
variability in routine testing. Therefore, it is suitable 
for simultaneous dissolution testing of ART and LUM 
from FDC ART/LUM tablets and can be effectively 
applied in quality control.
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